Too many options? Treat your friends and family to their favourite stores with a Bayshore Shopping Centre gift card, redeemable at participating retailers throughout the centre. Click below to purchase yours today!Purchase Here
Coles Convalescent Plasma and Other Antibody Therapies for Infectious Diseases: Lessons learned from COVID-19 Future Prospects at Bayshore Shopping Centre in Ottawa, ON
*Product information may vary - to confirm product availability, pricing, shipping and return information please contact Coles
This volume reviews key scientific principles and practices of passive antibody therapy for the treatment of infectious diseases. The main focus is on convalescent plasma, which is the most useful therapeutic option early in an epidemic, and may be especially important in low- and middle-income countries. The book&s first section reviews the history of passive antibody therapies prior to the COVID pandemic, while the second section assesses convalescent plasma use during the COVID pandemic including evidence for safety and effectiveness, factors affecting efficacy, and the importance of convalescent plasma treatment of COVID-19 infections in the immunosuppressed. This section also addresses the roles played in the pandemic by monoclonal antibodies and hyperimmune globulins. Section three discusses the logistics of retrieving, storing and delivering convalescent plasma for therapy, and section four considers the role of passive antibody therapies in the event of a new pandemic involving an unknown microbial pathogen. In March 2020 the editors of this volume founded the national COVID-19 convalescent plasma project (ccpp19), an association of academic physicians organized to investigate the safety and effectiveness of convalescent plasma and to facilitate access to its use in the treatment of this new international pandemic. Since that time, the project has produced more than 100 papers on almost every aspect of convalescent plasma usage in COVID-19 & treatment protocols, randomized trials, considerations of safety, conditions required for effectiveness, variability in use geographically and over time, application to vulnerable populations, regulatory issues, impact on overall COVID-19 mortality in the US and much else. At the same time, another form of antibody therapy & monoclonal antibodies & was being shown effective for out-patient use in COVID-19, confirming the principle of the value of antibody therapy in the early stages of disease, but lost effectiveness with viral mutation. A third form of antibody therapy & hyperimmune globulin, a preventive therapy with an excellent historical record of efficacy in several infectious diseases - holds great potential but was not effectively developed for COVID-19. This edited work brings together the central findings gained over the past years about passive antibody use and serves as an indispensable guide to best practices in the use of antibody therapies.
This volume reviews key scientific principles and practices of passive antibody therapy for the treatment of infectious diseases. The main focus is on convalescent plasma, which is the most useful therapeutic option early in an epidemic, and may be especially important in low- and middle-income countries. The book&s first section reviews the history of passive antibody therapies prior to the COVID pandemic, while the second section assesses convalescent plasma use during the COVID pandemic including evidence for safety and effectiveness, factors affecting efficacy, and the importance of convalescent plasma treatment of COVID-19 infections in the immunosuppressed. This section also addresses the roles played in the pandemic by monoclonal antibodies and hyperimmune globulins. Section three discusses the logistics of retrieving, storing and delivering convalescent plasma for therapy, and section four considers the role of passive antibody therapies in the event of a new pandemic involving an unknown microbial pathogen. In March 2020 the editors of this volume founded the national COVID-19 convalescent plasma project (ccpp19), an association of academic physicians organized to investigate the safety and effectiveness of convalescent plasma and to facilitate access to its use in the treatment of this new international pandemic. Since that time, the project has produced more than 100 papers on almost every aspect of convalescent plasma usage in COVID-19 & treatment protocols, randomized trials, considerations of safety, conditions required for effectiveness, variability in use geographically and over time, application to vulnerable populations, regulatory issues, impact on overall COVID-19 mortality in the US and much else. At the same time, another form of antibody therapy & monoclonal antibodies & was being shown effective for out-patient use in COVID-19, confirming the principle of the value of antibody therapy in the early stages of disease, but lost effectiveness with viral mutation. A third form of antibody therapy & hyperimmune globulin, a preventive therapy with an excellent historical record of efficacy in several infectious diseases - holds great potential but was not effectively developed for COVID-19. This edited work brings together the central findings gained over the past years about passive antibody use and serves as an indispensable guide to best practices in the use of antibody therapies.
Coles is renowned for its outstanding customer service and great selection of books. Along with the vast array of magazines, stationary, audio-books, children's literature, fiction, non-fiction and reference books, you can find accessories to make your reading experience more pleasurable. We can recommend the very best in reading today. We will help you search our titles for exactly what you need, and if we do not have it in stock, we will order it for you.
